ACXP News and Press, Acurx Pharmaceuticals Inc. From 07/12/22

Seres' $100 million share placement with strategic partners, including Nestle, helps stabilize the share price. The C. difficile market - how big is it? Who can compete with the Seres/Nestle (Aimmune Therapeutics) global rollout for C. difficile recurrence? Seres has had two share...

SER-109 has shown an excellent efficacy and safety profile but is entering a small and crowded market. SER-287 and SER-301 have shown no efficacy. SER-401 did not show efficacy in metastatic melanoma patients. SER-155 has not yet achieved proof of concept but is the most promi...

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2022 Earnings Conference Call May 11, 2022 8:30 A.M. ET Company Participants Rob Shawah - Chief Financial Officer David Luci - President and Chief Executive Officer Conference Call Participants Chad Yahn - Maxim Group Joanne Lee - Maxim Group Presentation...

Acurx Pharmaceuticals press release (NASDAQ:ACXP): Q1 GAAP EPS of -$0.26 beats by $0.07. Cash balance of $1.08M  as of March31, 2022 For further details see: Acurx Pharmaceuticals GAAP EPS of -$0.26 beats by $0.07

Acurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , May 11, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical sta...

Acurx Pharmaceuticals, Inc. to Discuss 2022 First Quarter Financial Results on May 11, 2022 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , April 29, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acur...

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2021 Results Conference Call March 17, 2022 08:30 AM ET Company Participants David Luci - President and CEO Rob Shawah - Co-Founder and CFO Conference Call Participants Jason McCarthy - Maxim Group Presentation Operator Greetings, and welcome to the Acurx...

Acurx Pharmaceuticals press release (NASDAQ:ACXP): FY GAAP EPS of -$1.49 beats by $0.20. Cash balance of $12.96M as of December 31, 2021 For further details see: Acurx Pharmaceuticals GAAP EPS of -$1.49 beats by $0.20

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , March 17, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), ...

Acurx Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28-30, 2022 from 9:00 a.m. - 5:00 p.m. EDT PR Newswire STATEN ISLAND, N.Y. , March 16, 2022 /PRNewswire/ -- Acurx Pharmaceuticals...